Loading
Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate.
Chengdu Zenitar Biomedical Technology appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2, 2, 3), testing Purinostat, Purinostat Mesylate, Selinexor, Flonoltinib in advanced solid tumor, recurrent and refractory diffuse large b-cell lymphoma, diffuse large b cell lymphoma，dlbcl, polycythemia vera (pv). OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.
Purinostat is an experimental investigational agent whose form is not stated in the registry from Chengdu Zenitar Biomedical Technology in phase 3 trials for diffuse large B-cell lymphoma and multiple myeloma, with its target not yet stated publicly.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.